Email: cspc@cspc.cn
Media
News Center
Apr. 15
2025
VOLUNTARY ANNOUNCEMENT - OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL
Apr. 14
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr. 11
SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr. 08
JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar. 21
SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 18
JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
